MHRAsafety guidance72% confidence
Opportunities for patients and the public to be involved in the work of the MHRA
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Cipla Ltd..
Regulatory Analysis
How we engage and involve patients and the public in our regulatory decision-making.
Supporting Context
- Therapeutic area
- Psychiatry · Major Depressive Disorder
- Sub-indication
- General
Related signal: Phase II Trial of Pramipexole vs Escitalopram for MDD in HIV Patients